Research programme: hormone therapies - Juniper Pharmaceuticals

Drug Profile

Research programme: hormone therapies - Juniper Pharmaceuticals

Alternative Names: Estrogen/progesterone intravaginal - Juniper Pharmaceuticals; JNP 0201; JNP 0301; Progesterone intravaginal - Juniper Pharmaceuticals

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Juniper Pharmaceuticals
  • Class Gonadal steroid hormones; Hormonal replacements
  • Mechanism of Action Estrogen receptor modulators; Progesterone receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Menopausal syndrome
  • No development reported Preterm labour

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Preterm-labour in USA (Vaginal, Ring)
  • 18 Sep 2017 Research programme: hormone therapies - Juniper Pharmaceuticals is available for licensing as of 18 Sep 2017. http://www.juniperpharma.com/
  • 26 Jan 2017 Juniper Pharmaceuticals announces its intention to file IND application with the US FDA for JNP 0301 in the first half of 2018
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top